PRESENTATION: Sitagliptin 50 mg /100 mg, Sitagliptin 50mg plus Metformin 500mg, Sitagliptin 100mg plus Metformin 500mg

DRUG CLASS: DPP4 Inhibitor and Bigaunides

MECHANISM OF ACTION:  Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4) enzyme resulting in prolonged active incretin levels. Incretin hormones (eg, glucagon-like peptide-1 [GLP-1] and glucose dependent insulinotropic polypeptide [GIP]) regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and decreasing glucagon secretion from pancreatic alpha cells.

Decreased glucagon secretion results in decreased hepatic glucose production. Under normal physiologic circumstances, incretin hormones are released by the intestine throughout the day and levels are increased in response to a meal; incretin hormones are rapidly inactivated by the DPP-4 enzyme.

INDICATIONS & DOSAGE: As Directed by the Physician